Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

Endogenous Pro-Resolving and Anti-Inflammatory Lipid Mediators: the New Hope of Atherosclerotic Diseases.

"Pro-Resolution" and Anti-Inflammation, A Role of Rve1 in Anti-Atherosclerosis and Plaque Stabilization

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Endothelial Foxp1 Suppresses Atherosclerosis Via Modulation of Nlrp3 Inflammasome Activation.

A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment

Identification of a Novel Series of Anti-Inflammatory and Anti-Oxidative Phospholipid Oxidation Products Containing the Cyclopentenone Moiety in Vitro and in Vivo: Implication in Atherosclerosis

Mechanistic insights into the regression of atherosclerotic plaques

Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis

The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification

Novel strategies to promote resolution of inflammation to treat lower extremity artery disease

Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.

LOX-1 in atherosclerosis: biological functions and pharmacological modifiers

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

High-density Lipoprotein and Inflammation and Its Significance to Atherosclerosis

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Development of synthetic lipoxin-A4 mimetics (sLXms): New avenues in the treatment of cardio-metabolic diseases

Targeting pro-inflammatory T cells as a novel therapeutic approach to potentially resolve atherosclerosis in humans

Atherosclerosis: cell biology and lipoproteins--new mechanistic links in atherosclerosis: chemokines mediating the effects of lipids, platelets and dendritic cells.